P1029 Janus Kinase Inhibitors for the Management of Acute Severe Ulcerative Colitis: A Multicentre Study
Robert Gilmore(The University of Queensland), Yoon‐Kyo An(Mater Hospital), Kathryn Demase(Alfred Health), Kannan Venugopal(Centre National de la Recherche Scientifique), W Mohsen, Adam Haig(Sunshine Coast University Hospital), Peter De Cruz(The University of Melbourne), Sami Aftab Abdul(Royal Adelaide Hospital), K MacFarlane(Royal Adelaide Hospital), Lena Thin(The University of Western Australia), Michael Day(Natural History Museum), Mayur Garg(Eastern Health), Moshe Loebenstein(Monash Health), Joshua F. Baker(Diabetes Australia), Deloshaan Subhaharan, Samantha M. Chin(Washington University in St. Louis), Kevin Lynch(Ollscoil na Gaillimhe – University of Galway), Jakob Begun(Translational Research Institute), Danny Con(Austin Health), Andrea Nguyen(Monash Health), Richard Fernandes(The University of Queensland), Gregory Moore(Monash Medical Centre), Miles Sparrow(Alfred Health), Sebastian Lucas(Northern Health), Robert V. Bryant(Queen Elizabeth Hospital), B. N. Tandon, Leigh White(Sunshine Coast University Hospital)
Cited by 3
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis
|PLoS Genetics|2013|217
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
|The Lancet|2017|198
Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study
|Journal of Crohn s and Colitis|2013|114
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis
|Inflammatory Bowel Diseases|2019|94